Article Text

Download PDFPDF

2 Efficacy and safety of lenvatinib plus pembrolizumab in patients with previously treated ovarian cancer in the multicohort phase 2 LEAP-005 study
  1. A González-Martín1,
  2. H Chung2,
  3. E Saada-Bouzid3,
  4. E Yanez4,
  5. H Senellart5,
  6. PA Cassier6,
  7. B Basu7,
  8. R Ghori8,
  9. P Kubiak9,
  10. A Smith10,
  11. K Norwood8 and
  12. Z Lwin11
  1. 1Clínica Universidad de Navarra, Spain
  2. 2Yonsei Cancer Center, Yonsei University College of Medicine, South Korea
  3. 3Department of Medical Oncology, Centre de Lutte Contre le Cancer Antoine Lacassagne, France
  4. 4Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Chile
  5. 5Institut de Cancérologie de l’Ouest, Centre René Gauducheau ICO, France
  6. 6Department of Medical Oncology, Centre Léon Bérard, France
  7. 7Department of Oncology, University of Cambridge, UK
  8. 8Merck and Co., Inc., USA
  9. 9Eisai Inc., USA
  10. 10Eisai Ltd., UK
  11. 11Royal Brisbane and Women’s Hospital, Australia


Introduction Lenvatinib, an antiangiogenic multiple receptor tyrosine kinase inhibitor, plus pembrolizumab, a programmed death-1 immune checkpoint inhibitor, demonstrated promising clinical benefit in a previous phase Ib/II trial across several cancer types (, NCT02501096). We assessed clinical outcomes with lenvatinib plus pembrolizumab in patients with ovarian cancer in the ongoing, open-label, multicohort, phase 2 LEAP-005 study (, NCT03797326).

Methods Female patients aged ≥18 years with histologically/cytologically confirmed, metastatic/unresectable ovarian cancer, measurable disease per RECIST v1.1, ECOG performance status 0/1, and 3 prior lines of therapy were enrolled. Patients received lenvatinib 20 mg daily plus pembrolizumab 200 mg every 3 weeks for 35 cycles, or until confirmed disease progression or unacceptable toxicity. Primary endpoints were objective response rate (ORR; response assessed every 9 weeks for 54 weeks, then every 12 weeks, by blinded independent central review per RECIST v1.1) and safety. Secondary endpoints included disease control rate, duration of response, and progression-free survival.

Results 31 patients with ovarian cancer received ≥1 dose of lenvatinib plus pembrolizumab in LEAP-005 (median age 62 years [range 40–76]); median study follow-up was 7.8 months (range, 4.6–12.4) as of April 10, 2020. ORR was 32% (95% CI, 17–51); other efficacy endpoints were also favorable (table 1). Treatment-related adverse events occurred in 29 (94%) patients (table 1).

Abstract 2 Table 1

Conclusion Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.